Is Day One Biopharmaceuticals Inc (DAWN) Stock About to Get Hot Thursday?

The market has been high on Day One Biopharmaceuticals Inc (DAWN) stock recently. DAWN gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Day One Biopharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on DAWN!

See Full DAWN Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With DAWN Stock Today?

Day One Biopharmaceuticals Inc (DAWN) stock has fallen -0.31% while the S&P 500 has gained 0.76% as of 3:24 PM on Thursday, Apr 7. DAWN is down -$0.04 from the previous closing price of $11.14 on volume of 179,850 shares. Over the past year the S&P 500 is up 7.49% while DAWN is down -57.09%. DAWN lost -$3.00 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Day One Biopharmaceuticals Inc click here.

More About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. Click Here to get the full Stock Report for Day One Biopharmaceuticals Inc stock.